LC–MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment
Analytical Chemistry · 2023
DOI: 10.1021/acs.analchem.3c02163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2023. Verfasst von Yunlin Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetic Sciences─Drug Disposition, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United Stat…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacokinetic Sciences─Drug Disposition, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States.
- Labcorp Drug Development, 3301 Kinsman Boulevard, Madison, Wisconsin 53704, United States.
- Pharmacokinetic Sciences─Drug Disposition, Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
ORCID-Profile: Yunlin Fu
Zitieren
APA
Fu, Y., Farnham, J., Li, W., Powers, B., Humphries, D., & Picard, F. (2023). LC–MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.3c02163
Vancouver
Fu Y, Farnham J, Li W, Powers B, Humphries D, Picard F. LC–MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment. Analytical Chemistry. 2023. doi:10.1021/acs.analchem.3c02163
BibTeX
@article{Fu2023,
author = {Fu, Yunlin and Farnham, James and Li, Wenkui and Powers, Brendan and Humphries, David and Picard, Franck},
title = {LC–MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment},
journal = {Analytical Chemistry},
year = {2023},
doi = {10.1021/acs.analchem.3c02163}
}
EUVIMED